INTRODUCTION {#sec1-1}
============

Developments in photonic technologies and an improved knowledge of light--tissue interactions have brought about considerable advances in mainstream medicine. Using high-dose lasers and light devices in medicine and dentistry is nowadays common for various clinical applications.\[[@ref1][@ref2][@ref3]\] However, a less prevalent clinical application is the use of low-dosage biophotonics for therapy, referred to as photobiomodulation (PBM) or formerly as low-level laser therapy (LLLT), which is intended for relieving pain and inflammation, regulating immune responses as well as stimulating wound healing and tissue regeneration.\[[@ref3][@ref4]\] In this manner, it presents an opportunity for a paradigmatic shift from conventional approaches to regenerative modalities in clinical dentistry. Although PBM initially received mixed responses,\[[@ref4]\] it is increasingly being recognized based on the accepted principles of photochemistry and cellular and molecular biology. The growing realization that PBM has a broad range of systemic and regional effects led to a striking increase in the number of its applications, with a special focus on its applications in dentistry.\[[@ref4][@ref5][@ref6]\]

In the field of oral implantology, research has been directed toward the potential of PBM to reduce the healing time following implant placement and to improve the potential of bone regeneration. Experimental studies have reported that PBM stimulates proliferation and differentiation of osteoblasts as well as it enhances bonding to titanium implant. In these studies, application of PBM in the early postoperative application was shown to improve the mechanical strength of the bone--implant interface and stimulate the bone matrix production.\[[@ref7][@ref8][@ref9][@ref10][@ref11]\] However, the usefulness of PBM application in dental implant clinical practice is not yet clear. Thus, this systematic review was conducted to answer the following research question formulated based on the population, intervention, comparator and outcome (PICO) criteria: "In patients receiving dental implants, does postoperative application of PBM improve osseointegration?"

MATERIALS AND METHODS {#sec1-2}
=====================

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).\[[@ref12]\] Based on the research question, the population was adult patients who had received dental implantation, the intervention was postoperative application of PBM and the comparator was control group. The principal outcome was successful osseointegration of dental implants in terms of improved implant stability, and secondary outcomes were anti-inflammatory and accelerated healing effects.

Search strategy {#sec2-1}
---------------

Two reviewers independently conducted an electronic search of PubMed, Cochrane Library and Embase for articles from inception up to January 10, 2020, using the following search terms: (dental implant OR dental implantology) AND (photobiomodulation OR low level laser therapy OR low level light therapy OR LLLT OR low intensity laser OR soft laser OR laser bio-stimulation) AND (osseointegration OR implant stability). No language filter was applied during the search. The title and abstracts of all articles in the searches were screened against the inclusion criteria to identify potentially eligible articles. Full texts of potential articles were read and assessed independently by the two reviewers. Any discrepancy was resolved through discussion until a consensus was reached. The inter-reviewers' reliability was calculated based on Cohen's kappa statistics. To detect any potential unidentified studies, bibliographies and reference lists of the included studies were also searched.

Inclusion/exclusion criteria {#sec2-2}
----------------------------

Randomized clinical trials (RCTs) and nonrandomized clinical studies that compared LLLT/PBM and other modalities such as ozone application on dental implant stability were included. Exclusion criteria were *in vitro* and animal studies, case reports, review articles, clinical studies on augmented implant sites and studies assessing a single type of treatment in the absence of a comparison group. In addition, to allow for reliable comparison, studies that applied orthodontic force on mini-implants were excluded to avoid its confounding effect on osseointegration and implant stability.

Data extraction {#sec2-3}
---------------

The two authors manually and independently extracted the data from each of the included studies; any disagreements in data extraction were resolved through discussion. The extracted data fields included first author name, year of publication, country where research was performed, study design, control group details, sample size, gender and mean age of patients, ethical approval, implant-related parameters (type, dimension and position), PBM parameters, number of PBM applications, analysis conducted, duration of follow-up and results.

Quality assessment {#sec2-4}
------------------

Methodological quality of the included studies was evaluated using the Cochrane Risk of Bias tool\[[@ref13]\] for RCTs and the Risk of Bias in Nonrandomized Studies-of Interventions (ROBINS-I) tool\[[@ref14]\] for nonrandomized studies.

RESULTS {#sec1-3}
=======

The initial database search yielded a total of 202 articles. All relevant articles were only published in English. After removal of duplicates and applying the inclusion/exclusion criteria, full-text articles of 15 relevant studies were thoroughly evaluated independently by the two reviewers. Eight studies\[[@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22]\] did not meet the eligibility criteria and were excluded \[[Table 1](#T1){ref-type="table"}\]. Eventually, seven studies were included for data synthesis \[[Figure 1](#F1){ref-type="fig"}\].

###### 

List of articles excluded after full-text assessment and reason for exclusion

  Study                                        Reason for exclusion
  -------------------------------------------- -------------------------------------------------------------------------
  Sleem *et al*., 2019\[[@ref15]\]             PBM combined with platelet-rich fibrin - which may influence PBM effect
  Flieger *et al*., 2019\[[@ref16]\]           Orthodontic mini-implants
  Marañón-Vásquez *et al*., 2019\[[@ref17]\]   Orthodontic mini-implants
  Arakeeb *et al*., 2019\[[@ref18]\]           PBM combined with growth factors
  Abohabib *et al*., 2018\[[@ref19]\]          Orthodontic mini-implants
  Mikhail *et al*., 2018\[[@ref20]\]           PBM combined with Vitamin C, omega-3 and calcium therapy
  Awad *et al*., 2017\[[@ref21]\]              Diabetic patients included in the study
  Yanaguizawa *et al*., 2017\[[@ref22]\]       Orthodontic mini-implants

PBM -- Photobiomodulation

![Flow diagram showing the screening and selection of articles](SJMMS-8-80-g001){#F1}

The Cohen's kappa value for inter-investigator agreement on the selected studies was 0.85. Owing to inconsistent data and substantial heterogeneity in the included studies, a meta-analysis was not possible, and thus a narrative synthesis of the included studies is presented.

General characteristics of the included studies {#sec2-5}
-----------------------------------------------

Of the seven studies included, five\[[@ref23][@ref24][@ref25][@ref26][@ref27]\] were RCTs and two were prospective clinical studies.\[[@ref28][@ref29]\] Three studies\[[@ref23][@ref24][@ref25]\] used the "split-mouth" experimental design, while the remaining studies separately included individuals as controls.\[[@ref26][@ref27][@ref28][@ref29]\] All studies were conducted between 2012 and 2019. Two studies were conducted in Turkey;\[[@ref28][@ref29]\] two in Iran;\[[@ref25][@ref26]\] and one each in Serbia,\[[@ref24]\] Poland\[[@ref27]\] and Brazil.\[[@ref23]\] All the included studies were conducted in academic research institutions after ethical approval; only one study\[[@ref25]\] did not report the ethical approval. The number of participants in the studies ranged from 8 to 25, while the age ranged from 20 to 64 years; one study\[[@ref25]\] did not report the mean age. Six studies enrolled healthy, nonsmoking patients with no systemic alterations, whereas the study by Gokmenoglu *et al*.\[[@ref28]\] did not exclude smokers. All the included studies evaluated the efficacy of PBM by comparing against a control group. Four studies\[[@ref23][@ref24][@ref26][@ref27]\] compared laser PBM against control group; one study each compared laser PBM and light-emitting diode (LED) PBM against control group,\[[@ref25]\] LED PBM against a control group,\[[@ref28]\] and ozone therapy to laser PBM and control group \[[Table 2](#T2){ref-type="table"}\].\[[@ref29]\]

###### 

Description of the included studies

  Point of comparison           Author                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  ----------------------------- ------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------
  Country                       Brazil                                                                                     Serbia                                                                                               Iran                                                                                                                        Iran                                                            Poland                                                         Turkey                                                                                                                                          Turkey
  Study design                  Split mouth (RCT)                                                                          Split mouth (RCT)                                                                                    Split mouth (RCT)                                                                                                           Different individuals (RCT)                                     Different individuals (RCT)                                    Different individuals (non-RCT)                                                                                                                 Different individuals (non-RCT)
  Control                       Placebo                                                                                    Placebo                                                                                              Placebo                                                                                                                     Placebo                                                         Placebo                                                        Placebo                                                                                                                                         Placebo
  Sample size                   8                                                                                          12                                                                                                   12                                                                                                                          19                                                              24                                                             15                                                                                                                                              25
  Gender                        2 males 6 females                                                                          6 males 6 females                                                                                    Not reported                                                                                                                9 males 10 females                                              16 males 8 females                                             9 males 6 females                                                                                                                               11 males 14 females
  Mean age (years), range       36, 20-55                                                                                  61.28, 55-75                                                                                         Not reported                                                                                                                Male: 40.8 Female: 43                                           46.7±8.7                                                       Control: 45.87+13.46 LED: 50.43+9.25                                                                                                            51.2±2.3, 36-64
  Ethical approval              Yes                                                                                        Yes                                                                                                  Not reported                                                                                                                Yes                                                             Yes                                                            Yes                                                                                                                                             Yes
  Implant type and dimensions   XiVE-S implants (Dentsply, Germany) Diameter: 3.8 mm Length: 11 mm                         Self-tapping implants BlueSky^®^ (Bredent, Germany) Diameter: 4 mm Length: 10 mm                     DIO implants (invasive fungal infectionstissue level) with resorbable blast media surface (Korea) Dimensions not reported   DIO UF implants (Korea) Diameter: 4-4.5 mm Length: 10-11.5 mm   Superline (Dentium, Korea) Diameter: 4.5 mm Length: 10-12 mm   XiVE-S implants (Dentsply, Germany) Control diameter: 3.8 (3.5-4.5) mm Length: 11 mm LED: Diameter: 4.5 (3.8-4.5) mm Length: 11.0 (10.6-11.0)   DTI Implant Systems (Turkey) Diameter: 4-4.5 mm Length: 10 mm
  Implant position              Posterior mandible                                                                         Posterior maxilla                                                                                    Anterior mandible                                                                                                           Posterior maxilla                                               Posterior mandible                                             Not reported                                                                                                                                    Posterior mandible
  Laser type and wavelength     GaAlAs 830 nm                                                                              GaAlAs 637 nm                                                                                        Diode 810 nm, LED 626 nm                                                                                                    Diode 940 nm                                                    Diode 635 nm                                                   LED 626 nm                                                                                                                                      GaAlAs 830 nm
  PBM parameters                86mW, CW 0.25 J, 3s/point, 20 points 0.0028 cm^2^, 3.71 W/cm^2^ 92.1 J/cm^2^, in contact   40mW, CW, 6.26 J/cm^2^ per implant Noncontact (1 cm)                                                 50mw, CW 50 mw/cm^2^ 20 J/cm^2^ In contact 185 mW, 38.5 mW/cm2, 46.2 J/cm^2^ Transcutaneous                                 100 mw, CW 354.6 mw/cm^2^, 14.18 J/cm^2^ In contact             100 mw, CW 0.5 cm^2^ 199.04 mW/cm^2^ 8 J/cm^2^ In contact      185 mW; 222 J; 20 min 38.5 mW/cm^2^; 46.2 J/cm^2^ Transcutaneous                                                                                86 mW, CW 0.0028 cm2, 0.25J per point, 3.71 W/cm^2^ 92.1 J/cm^2^, in contact
  Number of applications        7                                                                                          7                                                                                                    5                                                                                                                           6                                                               6                                                              9                                                                                                                                               7
  Analysis conducted            ISQ assessed by RFA                                                                        ISQ by RFA+ALP activity and early implant success rate                                               Implant stability By periotest + IL1β, PGE2                                                                                 ISQ assessed by RFA                                             Implant stability By periotest & Bone Density by CBCT          ISQ by RFA and IL-1β, TGF-b, PGE2, NO levels in peri-implant crevicular fluid                                                                   ISQ assessed by RFA
  Follow up                     12 weeks                                                                                   6 weeks                                                                                              8 weeks                                                                                                                     12 weeks                                                        12 weeks                                                       12 weeks                                                                                                                                        6 months
  Results                       No effect on implant stability                                                             No significant influence on osseointegration of self-tapping Implants placed into low-density bone   Positive effect on the stability of the implants 3 weeks and no effect on the level of IL1β and PGE2 in 4 and 8 weeks       No significant effect on dental implant stability               PBM enhanced secondary implant stability and bone density      Positive effect on osseointegration and implant stability In LED group, a negative correlation found between PGE2 and ISQ values                Positive effect on dental implant stability

RCT -- Randomized clinical trial; LED -- Light-emitting diodes; ISQ -- Implant stability quotient; RFA -- Resonance frequency analysis; IL-1β -- Interleukin-1β; TGF-β -- Transforming growth factor-β; PGE2 -- Prostaglandin-E2; NO -- Nitric oxide; ALP -- Alkaline-phosphatase; CBCT -- Cone-beam computed tomography

According to the Cochrane Risk of Bias tool, only two of the five randomized studies\[[@ref23][@ref24]\] were of low risk of bias, while the other three studies\[[@ref25][@ref26][@ref27]\] were of moderate risk of bias \[[Table 3](#T3){ref-type="table"}\]. The risk of bias of the two nonrandomized trials\[[@ref28][@ref29]\] was found to be moderate, according to the ROBINS-I tool \[[Table 4](#T4){ref-type="table"}\].

###### 

Risk-of-bias assessment of the included randomized clinical trials according to Cochrane Risk of Bias Assessment Tool

  Domain                                                      Authors                             
  ----------------------------------------------------------- --------- ----- --------- --------- ---------
  Random sequence generation (selection bias)                 \+        \+    \+        \+        \+
  Allocation concealment (selection bias)                     \+        \+    ?         ?         ?
  Blinding of participants and personnel (performance bias)   \+        \+    ?         ?         ?
  Blinding of outcome assessment (detection bias)             \+        \+    ?         ?         ?
  Incomplete outcome data (attrition bias)                    \+        \+    \+        \+        \+
  Selective outcome reporting (reporting bias)                \+        \+    \+        \+        \+
  Other potential threats to validity                         \+        \+    ?         \+        \+
  Risk of bias                                                Low       Low   Unclear   Unclear   Unclear

\+ -- Low risk of bias; ? -- Unclear risk of bias

###### 

Risk-of-bias assessment of the included nonrandomized clinical trials with the ROBINS-I tool

  ROBIN-I item                                         Study      
  ---------------------------------------------------- ---------- ----------
  Bias due to confounding                              Moderate   Moderate
  Bias in the selection of participants                Moderate   Low
  Bias in the classification of interventions          Low        Low
  Bias due to deviations from intended interventions   Low        Low
  Bias due to missing data                             Moderate   Low
  Bias in the measurement of outcomes                  Moderate   Moderate
  Bias in selection of the reported result             Low        Low
  Overall bias                                         Moderate   Moderate

Characteristics of treatment and methods used {#sec2-6}
---------------------------------------------

In terms of the implant systems used, two studies each used XiVE^®^-s (Dentsply, USA)\[[@ref23][@ref28]\] and DIO implant (South Korea),\[[@ref25][@ref26]\] and one study each used BlueSKY (Bredent, Germany),\[[@ref24]\] DTI implant system (Turkey)\[[@ref29]\] and Superline (Dentium, South Korea).\[[@ref27]\] Nevertheless, the implant dimensions used were very close; the length ranged from 10 to 12 mm and the diameter from 3.8 to 4.5 mm. Only one study\[[@ref25]\] did not report the implant dimensions used.

Mostly, the gallium aluminum arsenide\[[@ref23][@ref24][@ref29]\] and semi-conductor diode\[[@ref25][@ref26][@ref27]\] lasers were used, and LED was used in one study.\[[@ref28]\] A comparison between LED and diode was done in the study by Memarian *et al*.\[[@ref25]\]

Most studies used lasers in the near-infrared spectrum; however, the wavelengths differed: two studies used 830 nm\[[@ref23][@ref29]\] and one study each used 810 nm\[[@ref25]\] and 940 nm.\[[@ref26]\] Three studies used visible-range lasers with wavelengths of 626 nm and 637 nm.\[[@ref24][@ref27][@ref28]\] Follow-up period varied from 6 to 24 weeks, and the number of PBM applications ranged from 5 to 9. In terms of the jaw regions evaluated, three studies were performed on the posterior area of the mandible,\[[@ref23][@ref27][@ref29]\] two on the maxillary posterior\[[@ref24][@ref26]\] and one on the anterior mandible;\[[@ref25]\] one study did not state the specific irradiated area.\[[@ref28]\] Five studies examined the effect of PBM in terms of implant stability quotient by resonance frequency analysis (RFA),\[[@ref23][@ref24][@ref26][@ref28][@ref29]\] whereas the remaining two studies used periotest.\[[@ref25][@ref27]\] Three studies additionally examined biomarkers to augment their results.\[[@ref24][@ref25][@ref28]\]

Outcomes {#sec2-7}
--------

Four studies\[[@ref25][@ref27][@ref28][@ref29]\] reported that PBM application had a potential positive effect on the outcome of dental implant stability. On the other hand, three studies\[[@ref23][@ref24][@ref26]\] reported no significant influence, and there were no reports of adverse or negative effects of PBM. Therefore, a significant positive influence of PBM on osseointegration clinically was not established \[[Table 2](#T2){ref-type="table"}\].

DISCUSSION {#sec1-4}
==========

Dental implant stability depends on the implant's capacity to successfully osseointegrate, that is, successful bone-to-implant union while preserving the structural and functional integrity of the host site.\[[@ref30][@ref31][@ref32]\] PBM is increasingly being acknowledged in the literature for its potential beneficial effects in medicine and dentistry.\[[@ref3][@ref4][@ref33]\] Experimental studies have evaluated the use of PBM to stimulate osteoblast activity *in vitro* and concluded that PBM enhances the stability of dental implants. Furthermore, it was found to be capable of boosting the healing process around the surgical site by increasing adenosine triphosphate synthesis and angiogenesis, in addition to increasing the proliferation of osteoblast and reducing inflammation.\[[@ref31][@ref32][@ref33]\] Conversely, other articles had reported contradictory results.\[[@ref34][@ref35]\] Such discrepancies may be attributed to variations in the irradiation protocols and/or the experimental models used.\[[@ref4][@ref6][@ref36]\] However, given that humans have a different and more complex biological nature than experimental models, results from *in vitro* and animal models may not necessarily apply clinically.\[[@ref33]\] Accordingly, the current systematic review was envisioned to address a focused research question related to the clinical efficacy of PBM on dental implant osseointegration and stability.

Three studies used the split-mouth study design.\[[@ref23][@ref24][@ref25]\] Of these, García-Morales *et al*.\[[@ref23]\] reported that there was no evidence of PBM influencing the dental implant stability when measured by RFA. Nonetheless, the authors attributed the high primary stability and favorable bone quality to the rigid bone--implant interface, which may have concealed the effect of PBM. Similarly, Mandić *et al*.\[[@ref24]\] also reported no positive impact on self-tapping implants' osseointegration when placed into the low-density bone of the posterior maxilla. In this study, the spot size, irradiance and exposure duration were not reported. These parameters may have influenced the results. Moreover, the distance (10 mm) between the probe and tissues may have caused significant amount of laser energy to be reflected, thereby reducing the effectiveness of LLLT or rendering it ineffective. In contrast, Memarian *et al*.\[[@ref25]\] found that PBM by LLL or LED had a positive influence on dental implant stability 3 weeks post surgery. Although this study is of moderate risk of bias, its finding supports previous *in vivo* study on rabbit mandible, which used 830 nm wavelength at 20 J/cm^2^ and demonstrated a significant positive effect on new bone formation around dental implants inserted in the rabbit mandible.\[[@ref8]\]

Research using the split-mouth design for PBM is arguable owing to its potential systemic effect.\[[@ref37][@ref38][@ref39]\] Nonetheless, other studies were also found in the searches that used different individuals as control groups to exclude such systemic effect.\[[@ref26][@ref27][@ref28][@ref29]\] Karaca *et al*.\[[@ref29]\] used the same laser parameters previously used by García-Morales *et al*.,\[[@ref23]\] but in different individuals, and reported a positive influence on the healing of the bone surrounding immediately loaded implants and showed a clinically insignificant increase in implant stability. Nevertheless, the results of the later García-Morales *et al*.\[[@ref23]\] may be considered more reliable because of the more appropriate blinding and randomization, rendering it a high-quality study with lower risk of bias.

Gokmenoglu *et al*.\[[@ref28]\] also showed a positive impact of PBM on implant's osseointegration and stability. They reported that in the control group during the evaluation period, the primary stability revealed significant reduction. Conversely, an insignificant decrease in the primary stability was found in the LED group. In other words, PBM using LED may have maintained the primary implant stability. In the same vein, a more recent RCT\[[@ref27]\] concluded that PBM insignificantly improved secondary implant stability -- measured by periotest -- and significantly improved the bone density after 12 weeks at the middle and apical parts of the implant, as calculated by the cone-beam computed tomography. It is also worth noting that this study used a dose of 8 J/cm^2^ in the contact mode, which is within the recommended therapeutic window of PBM.\[[@ref4]\] In contrast, Torkzaban *et al*.\[[@ref26]\] found that postoperative application of PBM had no significant influence on the stability of dental implants. It is worth noting that they used irradiance of 354.6 mW/cm^2^, but the values recommended for stimulation and healing range from 5 to 50 mW/cm^2^;\[[@ref4]\] therefore, the insignificant effect may be explained by the biphasic response phenomenon.

The energy dose used in the studies included ranged from 6.2 to 92.1 J/cm^2^, thereby reflecting an absence of uniformity in the ideal dose for PBM. Moreover, the results are heterogeneous, indicating that the effectiveness of PBM on dental implants' stability and osseointegration remains controversial. This may be due to the diversity in the parameters used: energy density, number of applications, wavelength and power. This information is of importance for readers and researchers to be able to appraise the studies' results and the specific treatment applied.

The lack of consensus on the optimal PBM protocol for dental implants osseointegration may be due to different devices and different application protocols used. In addition, the results of this review should be interpreted cautiously owing to the presence of uncontrolled factors in the included studies such as intra- and inter-subject variations; for instance, the thickness and the light absorption characteristics of the intervening tissue affect the dose delivered at the target tissue. Nevertheless, a positive insignificant influence of PBM application on implant stability was reported in four studies,\[[@ref25][@ref27][@ref28][@ref29]\] which cannot be disregarded and warrants further research that controls for confounding factors to provide a clearer understanding. In addition, substantial efforts are necessary to achieve standardized clinical dosing and delivery protocols for PBM therapy to warrant the maximum efficacy and safety for PBM and allow for more conclusive studies with meta-analysis.

Regarding the impact of PBM on biomarkers and the inflammatory factors, Memarian *et al*.\[[@ref25]\] reported a significant decrease of both prostaglandin-E2 and interleukin-1β after 2 months. This is a natural phenomenon due to the decline in the inflammatory processes while healing is completed. However, PBM had no impact on the level of these inflammatory markers at different time intervals compared with the control group. Their results are consistent with those of Gokmenoglu *et al*.,\[[@ref28]\] which indicates that the PBM had no influence on the inflammatory factors. A possible explanation is that the influence of PBM on these factors may be considered effective in real infectious situations such as periimplantitis and not natural healing phenomenon of inflammation, i.e. it has no effect on the cells in homeostasis.\[[@ref40]\] Moreover, Mandić *et al*.\[[@ref24]\] showed that there was no statistically significant difference in the alkaline-phosphatase (ALP) activity between the test and control groups at all observation points. However, the pattern of ALP activity changes over time was different. In contrast to the control group, where continuous decrease of ALP activity was recorded, in the test group, after the initial decline, an increase was observed in the 4^th^ week. The increase in ALP activity in the laser group might be interpreted as an indication of enhanced osteoblast activity, and thus improved bone neo-formation and mineralization. This biochemical result may suggest a positive influence of PBM on osseointegration.

CONCLUSION {#sec1-5}
==========

This systematic review found that postoperative application of PBM may have a potential positive clinical influence on dental implants' osseointegration and stability. However, there were limited number of high-quality studies in addition to the diversity in methodologies and laser parameters used. Therefore, PBM protocols need to be standardized and additional RCTs with larger sample size and less intersubject variations should be performed to confirm the effectiveness of PBM on dental implants' osseointegration and stability.
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